Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Victorion-RIDES inclisiran in acute coronary syndrome
2025-521670-34-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Feb 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) comparing Inclisiran + high-intensity statin with Placebo + high-intensity statin (2 arms). Primary endpoint: Percent change in LDL-C from baseline to Day 150. Planned start Feb 2026; status: authorised.
02
Drugs
inclisiran
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2025-521670-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521670-34-00.